

**Table 2.1. Proportions of negative rRT-PCR assessments on day 14 and median times to negative rRT-PCR results after randomization in the multicenter, retrospective study.**

Group	N	Negative*	P-value* <sup>1</sup>	Median time to negative (Days, 95% CI)	P-value* <sup>2</sup>
HCQ	28	12 (42.9%)	0.70	15 (6,31)	0.37
Control	9	5 (55.6%)		14 (7,22)	

Abbreviations: HCQ: hydroxychloroquine; CI: confidence interval; \*Negative event: both pharyngeal swab and sputum showed negative results; #Time to negative = Event date or censored date – start day

\*1: Fisher’s exact test; \*2 Log-rank test stratified by clinical syndromes

**Table 3. Comparison of area under curve of Ct value between subjects in the HCQ and SOC groups in the multicenter, open-label, randomized controlled trial**

	HCQ (N=21)			SOC (N=12)			Treatment difference (95% CI)	Treatment effect, p value <sup>*1</sup>
	n	Mean (SD)	Median (range)	n	Mean (SD)	Median (range)		
Observed data	19	506.5 (43.7)	495.2 (424.0, 608.5)	11	501.6 (67.4)	495.1 (386.6, 594.5)	4.9 (-36.5, 46.3)	
Least square mean (SE)*		501.7 (18.0)			496.6 (21.1)		5.1 (-37.1, 47.2)	0.81

Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care; SD: standard deviation; CI: confidence interval;

\*Least Square means based on ANCOVA model with treatment effect.

SE is the standard error corresponding to the LSmean.

\*1: p-value: ANCOVA Model

**Table 4. Comparison of median times and negative viral rRT-PCR results between subjects in the HCQ and SOC groups presenting with mild symptoms in the multicenter, open-label, randomized controlled trial.**

Group	N	Negative	Median time to	P-value <sup>*1</sup>
			negative <sup>#</sup> (Days, 95% CI)	
HCQ	19	15 (78.9%)	5 (1,11)	0.31
SOC	10	8 (80.0%)	11 (1,12)	

Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care; CI: confidence interval;

\*Negative event: both pharyngeal swab and sputum showed negative results; <sup>#</sup>Time to negative = Event date or censored date – start day

\*1: Log-rank test

**Table 5 Comparison of times to clinical recovery between subjects in the HCQ and SOC groups in the multicenter, open-label, randomized controlled trial.**

Group	N	Clinical Recovery*	Median time to clinical	P-value <sup>*1</sup>	P-value <sup>*2</sup>
			recovery (Days, 95% CI)#		
HCQ	21	6 (28.6%)	.(9, .)	0.54	0.51
SOC	12	5 (41.7%)	.(5, .)		

Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care; CI: confidence interval;

\*Clinical recovery: 1<sup>st</sup> time of 3 consecutive PCR tests showed negative and major symptoms showed negative; #Time to clinical recovery = Event date or censored date – start day

\*1: Log-rank test

\*2: Log-rank test stratified by clinical syndromes.